Events, Pharmaceutical

Aptar Pharma Returns to DDL 2026 as Platinum Sponsor

17 Nov 2026

The annual three-day international conference focused on inhalation and pulmonary drug delivery science will be held at the Edinburgh International Conference Centre (EICC), UK. 

December 9 - December 11 2026 9:00 AM London / 4:00 AM New York
By: Ciara Jackson (Senior Marketing Manager External Communications, Aptar Pharma)
Share
17 Nov 2026
Aptar Pharma is Platinum Sponsor at DDL 2026

Aptar Pharma is pleased to return to DDL 2026 as a Platinum Sponsor, alongside Nanopharm, an Aptar Pharma company. Taking place December 9-11, 2026, at the EICC in Edinburgh, the DDL conference offers the opportunity to explore new research in nasal and pulmonary drug delivery, formulation, next-generation propellants and aerosol performance. 

Aptar Pharma will be at Booth 150 and Nanopharm at Aptar Pharma Services' Booth 194 throughout the three-day conference. The team from PULMOTREE, recently acquired by Aptar Pharma, will also be on hand to discuss the Kolibri™ Non-Propellant Liquid Inhaler platform and its potential to support next-generation inhaled therapies, including biologics. 

Podium lectures at DDL

Aptar Pharma will deliver two podium lectures at DDL this year: 

  • Session 5: Propellants, Planet & Patients: Clinical Needs and Advocacy - Thursday, 10 December  

Next-Generation Propellants in pMDIs: Why Valve Design Becomes a Critical Performance Driver will be presented by Lucas Silva, Director Business Development & Technology Pulmonary, Aptar Pharma (16:50 GMT). 

  • Session 6: Site-specific Aerosol Delivery - Friday, 11 December 

Towards Standardised Compendial Testing of Nasal Products: Multi-Laboratory Evaluation of the Kiel Nasal Inlet for Assessment of the <10 µm Fraction will be presented by Gonçalo Farias, Analytical and Innovation Hub Manager, Aptar Pharma (12:05 GMT). 

Four scientific posters 

Alongside the podium lectures, experts from Aptar Pharma and Nanopharm will also present posters on formulation development, nasal and pulmonary drug delivery, next-generation pMDIs and analytical science. 

The scientific posters will include: 

  • Development of Peptide Nasal Powders by Moisture-Activated Dry Granulation - Sana Hosseini, Aptar Pharma  
  • Predictive Modelling of Droplet and Particle Size Distributions for Spray-Dried Intranasal Powders - Sana Hosseini, Aptar Pharma  
  • Application of Design of Experiments for the Development of a Semi-Automated Method for pMDIs Using Next-Generation Propellants - Gregoire Deraime, Aptar Pharma  
  • Development of Oligonucleotide Powders for Intranasal and Pulmonary Delivery - Antonia Zapata del Baño, Nanopharm  

Delegates attending DDL 2026 can book a meeting with Aptar Pharma experts to discuss your nasal or pulmonary drug development challenges and find out how Aptar Pharma can support your next project. Contact Us